Literature DB >> 16202782

The influence of newborn screening for cystic fibrosis on pulmonary outcomes in new South Wales.

Karen O McKay1, Donna L Waters, Kevin J Gaskin.   

Abstract

OBJECTIVES: To determine whether early treatment of cystic fibrosis made possible by diagnosis after newborn screening results in improved pulmonary outcomes in adolescence. STUDY
DESIGN: Both screening (SG) and non-screening groups (NSG) comprised a cohort of children from Australia previously studied at 1, 5, and 10 years of age. The groups were compared on measures of clinical status obtained during their comprehensive annual review conducted at or near the 15th birthday of the subjects.
RESULTS: Data were collected on 48 of 57 original subjects in the NSG (7 had died; 2 were lost to follow-up) and 52 of 60 original subjects in the SG (4 had died; 2 transferred out of the country; 2 were lost to follow-up). Those dying in the SG were significantly older (by 48 months, P < .05) than those in the NSG. No statistically significant differences were found between the groups in nutritional status. However, subjects in the SG displayed statistically better total Shwachman-Kulczycki scores (7.0, P <or= .05), chest x-ray scores (2.3, P <or= .05) and lung function (forced expiratory volume in 1 second by 12.3%, P <or= .01; forced vital capacity by 12.6%, P <or= .01; and mean airflow by 23.3%, P <or= .01).
CONCLUSIONS: The previously observed advantage conferred by cystic fibrosis newborn screening on clinical outcomes in infancy and childhood is still apparent in adolescence.

Entities:  

Mesh:

Year:  2005        PMID: 16202782     DOI: 10.1016/j.jpeds.2005.08.013

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

Review 1.  Newborn screening for neuropathic lysosomal storage disorders.

Authors:  Wuh-Liang Hwu; Yin-Hsiu Chien; Ni-Chung Lee
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

2.  Extra corporeal membrane oxygenation (ECMO) therapy in a 3-year-old child with cystic fibrosis: a tale of hope.

Authors:  Patrick Stafler; Colin Wallis
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

3.  Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program.

Authors:  Sarah A Jadin; Grace S Wu; Zhumin Zhang; Suzanne M Shoff; Benjamin M Tippets; Philip M Farrell; Tami Miller; Michael J Rock; Hara Levy; HuiChuan J Lai
Journal:  Am J Clin Nutr       Date:  2011-03-23       Impact factor: 7.045

4.  Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.

Authors:  Olaf Sommerburg; Martin Lindner; Martina Muckenthaler; Dirk Kohlmueller; Svenja Leible; Reinhard Feneberg; Andreas E Kulozik; Marcus A Mall; Georg F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2010-08-17       Impact factor: 4.982

Review 5.  Background and Epidemiology.

Authors:  Don B Sanders; Aliza K Fink
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

6.  Cystic fibrosis: benefits and clinical outcome.

Authors:  K O McKay
Journal:  J Inherit Metab Dis       Date:  2007-07-06       Impact factor: 4.982

7.  Structures for clinical follow-up: newborn screening.

Authors:  R Rodney Howell; Gilian Engelson
Journal:  J Inherit Metab Dis       Date:  2007-08-10       Impact factor: 4.982

8.  Differences in immunoreactive trypsin values between type of feeding and ethnicity in neonatal cystic fibrosis screening: a cross-sectional study.

Authors:  Ernesto Cortés; Ana María Roldán; Antonio Palazón-Bru; María Mercedes Rizo-Baeza; Herminia Manero; Vicente Francisco Gil-Guillén
Journal:  Orphanet J Rare Dis       Date:  2014-11-07       Impact factor: 4.123

9.  Newborn screening alone insufficient to improve pulmonary outcomes for cystic fibrosis.

Authors:  Christina B Barreda; Philip M Farrell; Anita Laxova; Jens C Eickhoff; Andrew T Braun; Ryan J Coller; Michael J Rock
Journal:  J Cyst Fibros       Date:  2020-06-13       Impact factor: 5.482

Review 10.  Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis.

Authors:  Mirjam Stahl; Eva Steinke; Marcus A Mall
Journal:  Genes (Basel)       Date:  2021-05-25       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.